Seegene's latest marketcap:
As of 08/10/2025, Seegene's market capitalization has reached $997.83 M. According to our data, Seegene is the 9862th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 997.83 M |
| Revenue (ttm) | 317.06 M |
| Net Income (ttm) | 7.66 M |
| Shares Out | 46.11 M |
| EPS (ttm) | 0.17 |
| Forward PE | 21.29 |
| Ex-Dividend Date | 06/27/2025 |
| Earnings Date | 08/05/2025 |
Seegene's yearly market capitalization.
| Date | Market Cap(₩) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/10/2025 | ₩1.39 T | $997.83 M | 31.99% | 9862 |
| 12/30/2024 | ₩1.05 T | $703.37 M | -1.3% | 10799 |
| 12/28/2023 | ₩1.06 T | $819 M | -22.46% | 9808 |
| 12/29/2022 | ₩1.37 T | $1.08 B | -56.39% | 7883 |
| 12/30/2021 | ₩3.15 T | $2.64 B | -37.3% | 5176 |
| 12/30/2020 | ₩5.02 T | $4.62 B | 529.69% | 3007 |
| 12/30/2019 | ₩796.65 B | $685.12 M | 91.56% | 8504 |
| 12/28/2018 | ₩415.87 B | $370.13 M | -52.24% | 10656 |
| 12/28/2017 | ₩870.73 B | $809.78 M | -4.52% | 8105 |
| 12/29/2016 | ₩911.97 B | $747.81 M | -7.66% | 7789 |
Company Profile
About Seegene, Inc.
Seegene, Inc. is a global leader in molecular diagnostics, specializing in the manufacturing and distribution of innovative diagnostic solutions. Founded in 2000 and headquartered in Seoul, South Korea, the company focuses on developing cutting-edge products for disease detection and prevention.
Key Product Offerings
- Respiratory Disease Detection: Products designed to identify respiratory infections.
- Gastrointestinal Disease Detection: Solutions for diagnosing gastrointestinal tract infections.
- Human Papillomavirus (HPV) Detection: Advanced tests for HPV screening.
- Sexually Transmitted Infections (STI) Detection: Assays for identifying causative pathogens.
- Tuberculosis Detection: Specialized diagnostic tools for TB.
- Drug Resistance Products: Tests to detect antimicrobial resistance.
- Magicplex Sepsis Real-Time Test: A rapid diagnostic tool for sepsis-causing pathogens.
- Meningitis Detection: Products for diagnosing meningitis infections.
- SNP Detection: Tests for identifying SNPs in factor II, factor V, and MTHFR genes.
Strategic Collaborations
Seegene has partnered with Werfen to co-develop syndromic qPCR assays, enhancing its portfolio of diagnostic solutions.
With a commitment to innovation and global health, Seegene continues to expand its impact in the molecular diagnostics industry.
Frequently Asked Questions
-
What is Seegene's (KOSDAQ-096530) current market cap?As of 08/10/2025, Seegene (including the parent company, if applicable) has an estimated market capitalization of $997.83 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Seegene (KOSDAQ-096530) rank globally by market cap?Seegene global market capitalization ranking is approximately 9862 as of 08/10/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.